ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: FR-PO697

Relationship between B Cell Signatures and Disease Flare in Lupus Nephritis Patients

Session Information

Category: Glomerular

  • 1001 Glomerular: Basic/Experimental Immunology and Inflammation

Authors

  • Yap, Desmond Y.H., Queen Mary Hospital, Hong Kong, China
  • Yung, Susan, The University of Hong Kong, Hong Kong, China
  • Yam, Irene, The University of Hong Kong, Hong Kong, China
  • Lee, Paul, The University of Hong Kong, Hong Kong, China
  • Tam, Cheryl, The University of Hong Kong, Hong Kong, China
  • Chan, Daniel Tak Mao, Queen Mary Hospital, Hong Kong, China
Background

Nephritic flares in patients with lupus nephritis (LN) reduce renal survival but factors contributing to flares remain elusive. Perturbations of B cell subsets have been implicated in the pathogenesis of LN, but the relationship between B cell signatures and relapse has not been investigated.

Methods

We compared circulating B cell subsets and signatures (miRNA148a, BACH1, BACH2 and PAX5) in the serum and plasma cells during disease quiescence between Class III/IV±V LN patients who are multiple relapsers (MR, defined as ≥3 relapses within 36 months unrelated to non-compliance) or non-relapsers (NR, defined as no relapse after the presenting episode).

Results

33 patients were included (MR n=20; NR n=13). MR showed lower percentage of circulating naïve and memory B cells (0.48%, IQR 0.24%-3.15% vs. 4.52%, IQR 3.18%-8.25%; and 0.51%, IQR 0.26%-0.67% vs. 0.96%, IQR 0.86%-1.91%; p=0.014 and 0.014 respectively) and higher plasma cell-to-naïve B cell ratio (1.52±2.19 vs. 0.21±0.33, p=0.011) compared with NR. MR had higher miRNA148a in serum and plasma cells compared with NR [relative expression (RQ) 4.25±2.86 vs. 0.71±0.55 and 3.53±1.56 vs. 1.38±1.17, p=0.002 and 0.128] (Figure 1A). MR also showed lower BACH2 expression in circulating plasma cells [RQ 12.86±3.10 vs. 28.10±11.87, p=0.036)], but no difference in BACH1 and PAX5 (p>0.05 for both) (Figure 1B).

Conclusion

Elevated serum and plasma cell miRNA148a might be related to BACH2 downregulation in plasma cells and altered circulating B cell subsets, thereby increasing risk of LN relapse.